Peptides DB
Research-centric peptide and protocol reference hub

Eloralintide record · updated 6h ago

Metabolic & appetiteNeuro & moodGrade A · human clinicalResearch use only
All 21 studiesJump to the evidenceCompare
What is Eloralintide used for?

Eloralintide is a selective amylin receptor agonist that has been investigated for its potential role in the treatment of obesity. The mechanism of action involves the activation of amylin receptors, which are implicated in regulating appetite and glucose metabolism. By mimicking the effects of the naturally occurring hormone amylin, Eloralintide may help reduce food intake and promote weight loss through central nervous system pathways that influence satiety and energy expenditure.

How it works: Amylin receptor agonist

Primarily researched for · Metabolic & appetite

Development stage

where Eloralintide sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Current
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 27 registered trials. It describes the research record, not a recommendation.

Identity
NameEloralintide
Chain length—
Molecular weight4,526 Da
FormulaC201H319N49O65S2
Structure typeNot established
ClassMetabolic
Research levelWell Studied
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 175663130. No verified residue count for this compound.

Pharmacology
MechanismAmylin receptor agonist
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 6, 2026. How this works →
Research stats
Total studies21
Human / animal / cellular14 / 0 / 0
Highest trial phasePhase 3
Years covered2023–2026
Latest study16d ago
Publication history
20232026
Research funding
—no NIH grants found
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

21 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Links between personality functioning and post-traumatic stress disorder symptoms: a network analysis.
FindingE=0.31
Human2026Full text read0.80
Drivers of farmers' intentions to adopt genome-edited cassava resistant to cassava brown streak disease in Uganda.
FindingNot reported in abstract.
Human2026Full text read0.80
Barriers to satisfactory primary care contacts for Swedish cancer survivors: a cross-sectional survey.
Finding67% (1429/2131) reported one or more barriers to satisfactory primary care contacts.
Human2023Full text read0.80
Distinct correlates of post-traumatic stress disorder and subthreshold post-traumatic stress disorder considering a broad range of adverse experiences.
FindingPTSD prevalence was 15.0% among trauma-exposed individuals, n=461.
Human2026Full text read0.80
Real-world creatine supplementation: a large-scale cross-sectional study of use, knowledge, and experiences.
FindingMean satisfaction of 7.8/10.
Human2026Full text read0.80
Health service delivery and disease management across Ethiopian health care facilities: An evidence-based analysis of tuberculosis program performance and system determinants.
FindingPediatric TB detection was 2.1% vs. WHO's 12%.
review2026Full text read0.80
Clinical Outcomes and Predictors of Adverse Events in Influenza Patients Managed in a Hospital-at-Home Program: A 10-Year Retrospective Study.
Finding12.4% had ED visits at 30 days, n=270.
Human2026Full text read0.80
You are doubly excluded: the interplay of cyberostracism and perceived parental phubbing in predicting problematic smartphone use.
FindingNot reported in abstract.
Human2026Full text read0.80
Cue-induced inhibitory control in forensic patients with alcohol use disorder: A link to criminal recidivism risk assessed by factor 2 psychopathy.
Findingβ = -0.79, p = .004
Human2026Full text read0.80
The Dutch-translated Climate and Health Tool for nurses: cross-cultural adaptation and validation.
FindingNot reported in abstract.
review2026Full text read0.80
When violence meets leadership: Leadership climate as a buffer in the link between violence, harmful alcohol use, and burnout among healthcare workers in Sweden.
Findingb = 0.007, 95% CI [0.001, 0.016]
Human2026Full text read0.80
Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.
TakeawayNot reported in abstract.
—2025Title only0.10

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Eloralintide will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Eloralintide is discussed should be drawn from it.